Fewer than 20% of large employers are covering GLP-1 weight loss drugs like Ozempic, a new KFF analysis shows.

本研究从DR患者、小鼠和视网膜血管内皮细胞3个层面证明GLP-1 RA对DR的保护作用机制。我们的结果表明GLP-1 RAs信号对STING激活的抑制作用，从而改善内皮细胞炎症以及体内和体外的血管功能障碍，从而揭示了其 治疗DR 的潜力。

Research highlights how GLP-1 receptor agonists may improve brain health by targeting the neurovascular unit, linking ...

Background Clinical studies have shown that glucagon-like peptide-1 receptor agonists (GLP-1 RA) can have beneficial effects ...

KELOWNA, BC / ACCESSWIRE / October 8, 2024 / (NASDAQ:LEXX) & (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator ...

As more Americans are prescribed glucagon-like peptide-1 receptor agonist drugs, concerns are rising about how to best manage associated adverse ...

十一假期已过半，每年与国庆假期交叠且最受关注的全球性事件，少不了诺贝尔奖的颁布。自1901年开始颁发以来，诺贝尔奖基本已经成为了全球科学和文学领域的最高荣誉，也代表了对人类探索世界和未知的最高赞赏。据诺贝尔奖官网消息，2024年的诺贝尔奖将于10月7 ...

In real-world settings multiple factors contribute to non-persistence, including adverse effects, high cost-sharing and ...

On October 2, 2024, the U.S. Food and Drug Administration (FDA) determined the shortage of the tirzepatide injection, a glucagon-like peptide ...

Nasdaq-listed Amneal Pharmaceuticals, which already operates multiple manufacturing facilities in Gujarat, is further ...

Glucagon-like peptide 1 receptor agonists, more commonly known as GLP-1 medications, have dominated headlines for their ...

Learn how GLP-1 receptor agonists, now thriving in obesity treatment, could benefit from a more patient-friendly sublingual ...